Nabriva Therapeutics plc: Nasdaq/NYSE listing notice — Nabriva receives Nasdaq delisting notice; trading to suspend Aug 1, 2023

Nabriva Therapeutics plc

Stockholders' equity deficit of $(4,357,000) as of March 31, 2023 fails $2.5M minimum under Rule 5550(b)(1).
Nasdaq will suspend trading at open on August 1, 2023; Company will not appeal.
Ordinary shares may become eligible for Pink Open Market quotation, but no assurances given.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nabriva Therapeutics plc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

July 21, 2023, Nabriva Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, based on (i) the Company’s continued non-compliance with the Nasdaq Capital Market’s requirement to have a minimum stockholders’ equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the “Rule”) and (ii) the Company’s confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-083250

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.